Skip to main
  1. Stocks
  2. Protagonist Therapeutics
  3. Forecast
PTGX

Protagonist Therapeutics (PTGX) Stock Forecast & Price Target

Protagonist Therapeutics (PTGX) Analyst Ratings

Based on 14 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Protagonist Therapeutics is supported by two approved, royalty-generating assets that materially de-risk the story: Icotyde produced broad early launch momentum with more than 20,000 patients initiating therapy and nearly 9,000 prescribers, while Mimrylo added a second stream after approval in August and helped drive $274.4M of 3Q26 collaboration revenue and $3.07 diluted EPS. Its outlook is further strengthened by a well-capitalized balance sheet of $834.6M in cash, cash equivalents, and marketable securities, plus up to $300M of share repurchases, which should fund a wholly owned pipeline without immediate dilution. The pipeline adds upside through PN-881, PN-477, PN-458, and PN-8047, with clinically validated targets, encouraging Phase 1 data, and multiple readouts expected in 1Q27, early 1Q27, and 1H28.

Bears say

Protagonist Therapeutics is facing a negative outlook because its value depends heavily on unproven clinical programs and partnered commercialization, both of which carry meaningful execution risk if FDA or EMA approvals are delayed or denied. The company also faces intense competition in inflammation and immunology, including entrenched products and other oral candidates, which could restrict uptake for icotrokinra and any wholly owned assets, while higher-than-expected spending on the pipeline could pressure financial performance. Even rusfertide’s development is not without setbacks, as discontinuation rates due to treatment-emergent adverse events reached 5.5% versus 2.7% for placebo, and broader portfolio risk is amplified by the history of oral IL-17 failures and unpredictable regulatory outcomes.

Protagonist Therapeutics (PTGX) has been analyzed by 14 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Protagonist Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Protagonist Therapeutics (PTGX) Analyst Forecast & Price Prediction

Get the latest Protagonist Therapeutics (PTGX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Protagonist Therapeutics (PTGX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Protagonist Therapeutics (PTGX) Forecast

Analysts have given Protagonist Therapeutics (PTGX) a Strong Buy based on their latest research and market trends.

According to 14 analysts, Protagonist Therapeutics (PTGX) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $165.21, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $165.21, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Protagonist Therapeutics (PTGX)


Protagonist Therapeutics (PTGX) Analyst Forecast & Price Prediction

Get the latest Protagonist Therapeutics (PTGX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Protagonist Therapeutics (PTGX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover PTGX stock data and trends